Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company. The Company is engaged in development, manufacture and marketing of bio-equivalent pharmaceutical products, referred to as generics, in addition to the development of branded products. It operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceuticals Division (Impax Division). The Global Division concentrates its efforts on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Division is focused on the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders and the promotion of third-party branded pharmaceutical products. As of February 3, 2012, the Company had 65 abbreviated new drug applications (ANDAs) approved by the Food and Drug Administration (FDA).